ArticleBrain and behavior2025
Ability of SPP1 to Alleviate Post-Intracerebral Hemorrhage Ferroptosis via Nrf2/HO1 Pathway.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Osteopontin in the Central Nervous System: Roles in Development, Injury, Neurodegeneration, and Neuro-Oncology.Biomolecules · 2026Review
- Cell type resolved MR based on brain single cell eQTLs corroborated by single cell RNA sequencing uncovers neuroimmune and vascular programs in intracerebral hemorrhage.Journal of translational medicine · 2026Article
- Roles of cuproptosis in central nervous system tumors: from molecular mechanisms to therapeutic prospects.Frontiers in cell and developmental biology · 2026Review
- SPP1/OPN Alleviates Post-Intracerebral Hemorrhage Depression and Cognitive Impairment via Nrf2/BDNF Signaling Activation in Mice.CNS neuroscience & therapeutics · 2025Article
- PANoptosis: Cross-Talk Among Apoptosis, Necroptosis, and Pyroptosis in Neurological Disorders.Journal of inflammation research · 2025Review
- Exploring the complex mechanisms of post-intracerebral hemorrhage depression: towards personalized treatment approaches.Frontiers in psychiatry · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeThis study aimed to investigate the role of secretory phosphoprotein 1 (SPP1/OPN) in modulating iron-induced cell death (ferroptosis) following intracerebral hemorrhage (ICH). By integrating transcriptomic analysis and experimental validation, we sought to identify key molecular pathways and therapeutic targets associated with ferroptosis in ICH.
methodThe Gene Expression Omnibus Series GSE24265 dataset was analyzed using the limma package (R platform) to identify differentially expressed genes. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and Gene Ontology (GO) enrichment analyses were performed to elucidate biological functions. Genes associated with iron-induced mortality were identified by cross-referencing transcriptomic profiles with the FerrDb database. A protein-protein interaction network was constructed using Cytoscape, and hub genes were identified. An experimental ICH model was developed in mice using stereotactic instrumentation, and the effects of OPN administration were evaluated through neurological assessments, biochemical assays (superoxide dismutase, glutathione, malondialdehyde), Western immunoblotting (GPX4, ACSL4), Prussian blue histochemistry, and electron microscopy. FINDING: Transcriptomic analysis identified 27 hub genes, with CD44 and ITGB3 characterized as receptors for OPN. In the ICH model, OPN administration improved neurological outcomes, elevated antioxidant markers, and reduced lipid peroxidation. OPN upregulated GPX4 while suppressing ACSL4, indicating anti-ferroptotic effects. These protective effects were mediated through the Nrf2 pathway, as confirmed by inhibitor ML385. Prussian blue staining and electron microscopy demonstrated reduced cerebral iron deposition and mitochondrial damage following OPN treatment.
conclusionThis study provides novel evidence for SPP1/OPN as a key modulator of ferroptosis in ICH, highlighting its potential as a therapeutic target. By enhancing iron homeostasis and mitigating oxidative stress, OPN offers a promising strategy for improving outcomes in ICH patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.